Navigation Links
Adeona's Multiple Sclerosis Trial Receives $409,426 Grant
Date:3/28/2011

been recently diagnosed with relapsing-remitting MS. With 127 out of 150 patients enrolled in the clinical trial by March 1, 2011, the Company anticipates full enrollment by the second half of 2011. Additional information regarding this multiple sclerosis clinical trial is available at http://www.clinicaltrials.gov/ct2/show/NCT00451204.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer's disease, and drugs for multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis. For more information, please visit Adeona's website at www.adeonapharma.com.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "could," "potential," "positions," "continue," "expects," "anticipates," "intends," "plans," "believe," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding our ability to produce a new, effective oral therapy for multiple sclerosis and the anticipated enrollment. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-l
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
(Date:7/30/2015)... PARSIPPANY, N.J. , July 30, 2015  Growth ... Rx-to-OTC switches as they bring former prescription users to ... environment, Kline forecasts robust Rx-to-OTC switch activity ... OTC categories emerging along with many new brands entering ... switches occur over the next five years (even those ...
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... AcelRx Pharmaceuticals, Inc. announced today that it has filed ... and Exchange Commission (SEC) relating to a proposed initial public ... the common stock to be sold in the offering will ... Co. is acting as sole book-running manager. Canaccord Genuity Inc., ...
... Nov. 12, 2010 WebMD Health Corp. (Nasdaq: ... will deliver a presentation at the Citi 7th Annual U.S. ... p.m. ET and Anthony Vuolo, COO and CFO, will join ... analysts and the general public are invited to listen to ...
Cached Medicine Technology:
(Date:8/1/2015)... ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive ... the Appalachian Trail by stepping off Springer Mountain and heading north. Since that ... 26th Phil reached Connecticut and was greeted by friends and family. He visited CCAR ...
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium ... day each year is the Super Bowl. In the two weeks that separate the conference ... host venue. The 2016 Super Bowl game will mark the 50th time it has been ...
(Date:7/31/2015)... ... ... The 2nd annual Ride to Fight On will start and end near the ... to Fight On is a cycling fundraiser that benefits the West Cancer Center, a ... University of Tennessee Health Science Center. A health and wellness festival featuring food, music, ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... Coco ... the athletes, judges, media, and VIPs at the 2015 Vans US Open of Surfing, ... coconut water that can claim “no added sugar” on the market, is a natural ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique ... wedding cakes with custom designs, making life just a little bit sweeter ... wedding cakes for each customer who orders one. , The bakery provides a full ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... FRIDAY, Jan. 28 (HealthDay News) -- People who have ... have difficulty showing empathy, and new research shows that ... deficiency. The finding suggests that psychopaths may benefit ... brain injury patients, said the researchers at the University ...
... one step closer to understanding how the rhythm of ... including some antibiotics, antihistamines and anti-psychotics, can cause a ... 40-50% of all drugs in development will block one ... heart and, as a result, can cause heart rhythm ...
... , , , , , , ... , , , ... do whatever they can to play in the... , Click here for more information. ... , , , , , , ...
... today, the American College of Physicians (ACP) offered more ... a process that it hopes will lead to consensus ... evidence of clinical effectiveness and value. How Can ... and Efficiently?, is, to ACP,s knowledge, the first time ...
... , People with addictions to stimulants tend to choose instant ... benefit, even if the future reward is greater. Reduced ... is the major challenge for treatment of addiction. A new ... Biological Psychiatry appears to present a strategy for increasing ...
... of Medicine and Dentistry (PCMD), University of Exeter, is one ... a 6m research and analysis network, funded by the EU ... possible role of virus infection in the cause of type ... to the development of a vaccine to prevent diabetes in ...
Cached Medicine News:Health News:Victor Chang scientists unlock the 'gates' on sudden cardiac death 2Health News:Retired NFL players misuse painkillers more than general population 2Health News:Retired NFL players misuse painkillers more than general population 3Health News:Retired NFL players misuse painkillers more than general population 4Health News:Retired NFL players misuse painkillers more than general population 5Health News:New principles from ACP to determine consensus on conserving and allocating health resources 2Health News:New principles from ACP to determine consensus on conserving and allocating health resources 3Health News:Memory training explored as strategy for addiction treatment 2Health News:Memory training explored as strategy for addiction treatment 3Health News:6 million euros for European Diabetes Research Network 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: